- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01621685
Human Safety of Capsaicin Inhalation Challenge Testing for Young and Older Men (Capsaicin)
The Role of Age on the Human Cough Reflex
Study Overview
Detailed Description
After a research subject's death during an inhalation study using medications/drugs not approved for this route, the FDA prohibited human use of non-approved chemicals including capsaicin administered via inhalation.
Capsaicin inhalation challenge tests (CICT) were performed on forty men of different ages utilizing pharmaceutical grade Capsaicin. Solutions were mixed by a registered pharmacist and Capsaicin doses, administered to subjects, were analyzed by high performance liquid chromatography (HPLC). Capsaicin solutions were stored in a refrigerator at 4 degrees C and shielded from ultraviolet light for 7 months. There was serial monitoring by spirometry and impulse oscillometry, electrocardiography, blood pressure, pulse and oxygen saturation measurements.
There were no adverse reactions at any dose, including the highest capsaicin concentration. Serial spirometry and impulse oscillometry, electrocardiography, blood pressure, pulse and oxygen saturation measurements did not change. The actual amount of pharmaceutical-grade capsaicin measured was 85.5% of the concentrations estimated by the registered pharmacist at time of mixing. The difference was more for the lowest 0.49 uMol dose (28.1) compared to a 2.2% lesser concentration for the 1000 uMol solution. Capsaicin concentrations fell after 3 months of storage.
Dilute capsaicin aerosol inhalation is relatively innocuous and CICT is safe. The actual amount of pharmaceutical-grade capsaicin inhaled by subjects is less than the estimate at mixing. Capsaicin loses potency after 3-months of protected storage. Inhalation studies involving non-approved drugs or chemicals/medications can be safely conducted when they follow the appropriate safety procedures such as described in this investigation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- College of Public Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men of ages 18 and 30 (Dates of birth 1973-1985) or 55-92 years old (Dates of birth 1911-1948).
- Must not currently be a cigarette smoker. If an ex-smoker then has not smoked for at least 10 years and consumption were no more than 10 pack years.
- Agrees to volunteers for the study and willing to sign the informed consent form.
There were negative/normal screening tests for the following
- Responses to the questionnaire deny current and prior respiratory diseases (including asthma, emphysema, chronic bronchitis, sinusitis and interstitial lung d9sase) and no current respiratory complaints (e.g., cough, wheezing, shortness of breath, allergic rhinitis, and sinusitis). Subjects must not be taking any cardiac medications or admit to a physician-diagnosed cardiac condition.
- "Normal" spirometry measurements with FEV1 & FVC greater than 75% predicted and FEV1/FVC more than 69%
- Impedance oscillometry were within normal limits
- "Negative" physical examination of the chest with absence of wheezing and crackles on auscultation of the chest.
- Exhaled nitric oxide concentration is less than 35 ppb for younger and less than 65 ppb for older groups
Exclusion Criteria:
- men of: ages < 18, 31-54 and >92 years old;
- current cigarette smokers or exsmokers who have smoked within the past 10 years and/or smoked more than 10 pack/years;
- refusal to volunteer for the study and not willing to sign the informed consent form;
screening test not considered "normal" by physician/PI and showing one or more of the following:
- one or more positive response to the questionnaire(e.g., current or past respiratory diseases including asthma, emphysema, chronic bronchitis, sinusitis and interstitial lung disease; and/or; current respiratory complaints (e.g., cough, wheezing, shortness of breath, allergic rhinitis, and sinusitis) and/or; admitting to taking a cardiac medication and/or; or physician-diagnosed cardiac condition (e.g., coronary heart disease, angina, myocardial infarction, valvular heart disease, cardiomyopathy, etc.);
- Abnormal spirometry measurements (FEV1 &/or FVC <75% predicted and FEV1/FVC <69%);
- "Positive" physical examination (performed by Physician/PI) with presence of wheezing and/or crackles on auscultation of the chest;
- Impulse oscillometry >4 times normal limits;
- Exhaled nitric oxide of >35ppb for younger group and >65 ppb for older group. -
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Spirometry, auscultation, questionnaire
>12% fall in FEV1, wheezing on auscultation, symptom questionnaire score >4
|
Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
>12% Fall In FEV1
Time Frame: Baseline and >5 coughs 2-minutes after each inhaled capsaicin dose
|
Single breaths of capsaicin were delivered in ascending order, with normal saline solution randomly interspersed to increase challenge blindness, until two (C2) and five (C5) or more coughs were reached.
The different concentrations were delivered at 2 minute intervals.
After each inhalation dose the following were performed: FEV1 measurement, administer of the symptom questionnaire and auscultation of the chest for wheezing.
|
Baseline and >5 coughs 2-minutes after each inhaled capsaicin dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptom Questionnaire
Time Frame: Repeatedly over 1 week
|
Over a 1-week period, repeated telephone calls recorded responses to 6 questions.
Subjects were asked post-inhalation symptoms of: (1) heavy or difficulty in breathing; (2) phlegm production: (3) runny or irritated nose; (4) throat irritation or burning: (5) feeling of a weight or tightness of the chest; and, (6) feeling of chest burning.
Any subject reporting continued symptoms of category #4 (i.e., very severe) for two or more items, compared to the baseline was asked to return for more detailed evaluation.
|
Repeatedly over 1 week
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stuart M. Brooks, MD, University of South Florida
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IND# 69,642
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COPD
-
University Medical Center GroningenCompleted
-
Istituto Nazionale di Ricovero e Cura per AnzianiRecruiting
-
Bio-Sensing Solutions S.L. (DyCare)Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; Centre...Not yet recruiting
-
Sir Run Run Shaw HospitalRecruiting
-
University Hospital, BrestRecruiting
-
The First Affiliated Hospital of Guangzhou Medical...Recruiting
-
Association des Réseaux BronchioliteLaboratoire Système et Matériaux pour la Mécatronique (SYMME)Recruiting
-
Baylor Research InstituteNot yet recruiting
-
Polytechnic Institute of PortoNippon Gases PortugalRecruiting
Clinical Trials on biological/vaccine
-
Mahidol UniversityBioNet-Asia Co., Ltd.Completed
-
Tongji UniversityShanghai Pharmaceuticals Holding Co., LtdActive, not recruitingAdvanced Hepatocellular CarcinomaChina
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Unknown
-
Inmunotek S.L.Unidad de Investigacion Medica en Epidemiologia ClinicaCompletedBronchospasm; Bronchiolitis | Bronchospasm; BronchitisSpain
-
Valneva Austria GmbHCompletedChikungunya Virus InfectionUnited States
-
Green Cross CorporationUnknownWhooping Cough | Tetanus | DiphtheriaKorea, Republic of
-
BioNTech SEPfizerCompletedSARS-CoV-2 Infection, COVID-19United States, Spain, Finland, Poland, Mexico, Brazil
-
Lisata Therapeutics, Inc.Terminated
-
Talaris Therapeutics Inc.Northwestern UniversityNo longer availableRenal FailureUnited States
-
Nykode Therapeutics ASATheradex; Vaccibody ASCompletedHigh Grade Cervical Intraepithelial NeoplasiaGermany